Full Name
interferon gamma.
Background
Produced by lymphocytes activated by specific antigens or mitogens. IFNgamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Alternative Names
IFNγ, IFN-gamma
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IFNG include Hepatitis C Virus and Tuberous Sclerosis 2.
Related Pathways
Its related pathways are Folate Metabolism and Tuberculosis.
Function
Produced by lymphocytes activated by specific antigens or mitogens. In addition to the antiviral activity of ifn-gamma, it also has important immune regulation functions. It is a strong activator of macrophages, has an anti-proliferation effect on transformed cells, and can enhance the antiviral and antitumor effects of type I interferon.
Post-translational modifications
Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
Emapalumab, trade name Gamifant, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab was developed by NovImmune SA and Sobi and approved on November 20, 2018 for the treatment of hemophagocytic lymphohistiocytosis (HLH).
Indication
Progressive, refractory, primary intolerance with conventional therapy
Recurrent Hemophagocytic Lymphohistiocytosis
